AfterRaise/Companies/Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals is a clinical-stage biotechnology company developing cerebroprotective therapies for concussion, traumatic brain injury (TBI) and stroke. From its funding announcement.

$10M Series BRaised yesterdayGroton, USABiotech & PharmaUSA
Visit website →

In their own words

What Astrocyte Pharmaceuticals says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage biotechnology company developing cerebroprotective therapies for concussion, traumatic brain injury (TBI) and stroke". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Astrocyte Pharmaceuticals is today

Astrocyte Pharmaceuticals announced a Series B round of $10M on 30 September 2026, led by DeepWork Capital.

Latest round
Series B
Amount
$10M
Announced
30 September 2026
Headquarters
Groton, USA
Sector
Biotech & Pharma
Investors
Also participating
MintPharma Capital, Waterstar Capital, Dynagrow Capital, Star Ventures
Relevant leadership
CEO William Korinek

Momentum AfterRaise intelligence

AfterRaise Score

66
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
8/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 30 September 2026
    $10M Series B
    Led by DeepWork Capital.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Commercial scale-up
  • New market preparation

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Series B round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 30 September 2026$10M Series B announced
  • 30 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Astrocyte Pharmaceuticals is open to

Not yet specified

Astrocyte Pharmaceuticals has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Astrocyte Pharmaceuticals

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Astrocyte Pharmaceuticals?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector